Anzeige
Erschienen in:
01.12.2017 | Original Article
Uptake of AV-1451 in meningiomas
Erschienen in: Annals of Nuclear Medicine | Ausgabe 10/2017
Einloggen, um Zugang zu erhaltenAbstract
Aim
AV-1451 is an imaging agent labeled with the positron-emitting radiolabel Fluorine-18. 18F-AV-1451 binds paired helical filament tau (PHF-tau), a pathology related to Alzheimer’s disease. In our study of AV-1451 uptake in the brains of cognitively normal subjects, we noted a case of a meningioma with visually significant uptake of AV-1451.
Objective
We initiated the present retrospective study to further examine cases of meningioma that underwent AV-1451 imaging.
Methods
We searched the patient records of 650 patients who had undergone AV-1451 at our institution for the keyword “meningioma” to identify potential cases. PET/CT and MRI results were visually reviewed and semi-quantitative analysis of PET was performed. A paired student’s t test was run between background and tumor standard uptake values. Fisher’s exact test was used to examine the association between AV-1451 uptake and presence of calcifications on CT.
Results
We identified 12 cases of meningioma, 58% (7/12) of which demonstrated uptake greater than background using both visual analysis and tumor-to-normal cortex ratios (T/N + 1.90 ± 0.83). The paired student’s t test revealed no statistically significant difference between background and tumor standard uptake values (p = 0.09); however, cases with a T/N ratio greater than one showed statistically higher uptake in tumor tissue (p = 0.01). A significant association was noted between AV-1451 uptake and presence of calcifications (p = 0.01).
Conclusion
AV-1451 PET imaging should be reviewed concurrently with anatomic imaging to prevent misleading interpretations of PHF-tau distribution due to meningiomas.